Kukdong "Hyumap Develops Recombinant Mouse Embryonic Stem Cells for Jinteje Prototype"

[Asia Economy Reporter Hyunseok Yoo] Kookdong announced on the 13th that its affiliate Humap has succeeded in developing a prototype of the human antibody-producing transgenic mouse platform ‘SynTheseTM’.

Humap confirmed mouse embryonic stem cells carrying the human antibody gene light chain (hIgK), one of the three human antibody genes, by utilizing AiCE (Allogeneic Large-scale Genome Replacement Technology), an original core technology developed for the first time in the world.

The AiCE technology used to produce SynThese mice is a method that can replace large-scale genomes at once, unlike the conventional gene engineering method using BAC libraries. It is a revolutionary next-generation technology that can shorten the production period of about 10 years to 2 to 3 years, attracting great attention.

A Humap official said, “The special significance of this prototype is that it proves the possibility of producing a human antibody-producing transgenic platform using AiCE technology independently developed only by Humap, avoiding existing patented technologies monopolized and dominated by global competitors.”

He added, “By repeating the same method and process to replace the remaining heavy chain, the genuine product will be completed, so this prototype alleviates investors’ concerns about the success potential of the genuine product.”

The transgenic mouse platform SynTheseTM replaces the entire set of antibody genes in mice with human antibody genes, enabling the derivation of fully human therapeutic antibodies with a high likelihood of clinical success.

A Kookdong official emphasized, “With Humap’s success in this prototype, the joint antibody drug development cooperation program between the two companies will now officially begin.”